cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.13606607.v2
title: Laelatu dataset containing two Illumina MiSeq runs

description: Laelatu testset contains 36 samples and two Illumina MiSeq runs: (i) arbuscular mycorrhizal fungal (AMF) reads and (ii) general eukaryote (F574) + general fungal ITS (ITS) reads. For each set sample sheets are provided in files AMF.txt, F574.txt and ITS.txt. Sample sheets are tab-delimeted, where columns from 1st to 5th are following: sample name, forward barcode sequence, forward primer sequence, reverse barcode sequence and reverse primer sequence.<br>AMF.txt sample sheet file has to be used with following FASTQ files: AMF_R1.fq.gz (forward reads containing forward primer and sequence), AMF_R2.fq.gz (forward reads containing barcode), AMF_R3.fq.gz (reverse reads containing barcode) and AMF_R4.fq.gz (reverse reads containing reverse primer and sequence).<br>F574.txt and ITS.txt sample sheet files have to be used with following FASTQ files: F574+ITS.R1.fq.gz (forward reads containing forward primer and sequence), F574+ITS.I1.fq.gz (forward reads containing barcode), F574+ITS.I2.fq.gz (reverse reads containing barcode) and F574+ITS.R2.fq.gz (reverse reads containing primer and sequence).<br>gDAT (github.com/ut-planteco/gDAT) pipeline supports usage of packed files (*.gz). Follow pipeline manual located in the manual/ folder how to proceed with the data analyses.
DOI: 10.6084/m9.figshare.13606607.v1
title: Laelatu dataset containing two Illumina MiSeq runs

description: Laelatu testset contains 36 samples and two Illumina MiSeq runs: (i) arbuscular mycorrhizal fungal (AMF) reads and (ii) general eukaryote (F574) + general fungal ITS (ITS) reads. For each set sample sheets are provided in files AMF.txt, F574.txt and ITS.txt. Sample sheets are tab-delimeted, where columns from 1st to 5th are following: sample name, forward barcode sequence, forward primer sequence, reverse barcode sequence and reverse primer sequence.<br>AMF.txt sample sheet file has to be used with following FASTQ files: AMF_R1.fq.gz (forward reads containing forward primer and sequence), AMF_R2.fq.gz (forward reads containing barcode), AMF_R3.fq.gz (reverse reads containing barcode) and AMF_R4.fq.gz (reverse reads containing reverse primer and sequence).<br>F574.txt and ITS.txt sample sheet files have to be used with following FASTQ files: F574+ITS.R1.fq.gz (forward reads containing forward primer and sequence), F574+ITS.I1.fq.gz (forward reads containing barcode), F574+ITS.I2.fq.gz (reverse reads containing barcode) and F574+ITS.R2.fq.gz (reverse reads containing primer and sequence).<br>gDAT (github.com/ut-planteco/gDAT) pipeline supports usage of packed files (*.gz). Follow pipeline manual located in the manual/ folder how to proceed with the data analyses.
DOI: 10.25646/7876
title: Tagesdaten-CSV aus dem DIVI-Intensivregister

description: Die Tagesdaten-CSV entspricht einem Auszug der Daten des DIVI-Intensivregisters. Die Datei enthält eine Aggregation der aktuellsten Meldungen pro Landkreis. Es werden die aktuell gemeldeten Anzahlen der COVID-19 Intensivfälle sowie die gemeldeten intensivmedizinischen Behandlungskapazitäten angezeigt. Die Tagesdaten-CSV liefert dabei ausschließlich einen Blick auf die Daten gemäß dem Stand des betrachteten Tages. Die Daten sind im situationsbedingten Kontext aufbereitet, damit sind verschiedene Tagesdaten-CSVs u.U. nicht direkt miteinander vergleichbar. Die aktuellsten Meldungen werden im gewählten Betrachtungszeitfenster über alle Meldebereiche und Standorte aufsummiert. Weitere Informationen sind zu finden unter https://www.intensivregister.de/#/faq
DOI: 10.6084/m9.figshare.13207604
title: Keteleeria davidiana var. calcarea.zip

description: Maximum likelihood phylogenomic tree inferred from <i>K. calcarea</i> and other 19 species within Pinaceae and one out group species (<i>E. foeminea</i>) using complete chloroplast genomes.
DOI: 10.15468/p7z44z
title: First fossil Eriocottidae discovered in Eocene Baltic amber (Insecta: Lepidoptera)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Ngô-Muller, Valerie, Engel, Michael S., Nel, Andre, Nel, Jacques (2020): First fossil Eriocottidae discovered in Eocene Baltic amber (Insecta: Lepidoptera). Zootaxa 4834 (2): 273-282, DOI: https://doi.org/10.11646/zootaxa.4834.2.7
DOI: 10.6084/m9.figshare.13606196.v1
title: BC shape models by EMBS

description: The dataset of figures in the paper "<i>Constructing shapes and mixing structures of black carbon particles with applications to optical calculations</i>"
DOI: 10.5281/zenodo.3983553
title: PNAS_PolarPatterns

description: Pattern formation and polarity sorting of driven actin filaments on lipid membranes (PNAS) Contains: An Excel sheet containing the collisions statistics and the alignment of filaments over time A SLB_FRAP_DATA folder the raw data to estimate the diffusion coefficient from FRAP experiments on SLBs using the script contained in SCRIPTS.zip A POLARITY folder containing the recovery curves for streams, vortices etc. and a script (in SCRIPT.zip) to plot the asymmetry parameter P tif files of the experiments. Includes: - Tif files at different (surface) deensity. The bulk density is given in the title - Tif files of FRAP experiments at different (surface) density. The bulk density is given in the title
DOI: 10.5281/zenodo.3983552
title: PNAS_PolarPatterns

description: Pattern formation and polarity sorting of driven actin filaments on lipid membranes (PNAS) Contains: An Excel sheet containing the collisions statistics and the alignment of filaments over time A SLB_FRAP_DATA folder the raw data to estimate the diffusion coefficient from FRAP experiments on SLBs using the script contained in SCRIPTS.zip A POLARITY folder containing the recovery curves for streams, vortices etc. and a script (in SCRIPT.zip) to plot the asymmetry parameter P tif files of the experiments. Includes: - Tif files at different (surface) deensity. The bulk density is given in the title - Tif files of FRAP experiments at different (surface) density. The bulk density is given in the title
DOI: 10.5281/zenodo.3993062
title: Self-absorption of synchrotron radiation in a laser-irradiated plasma

description: Data and code required to reproduce the simulation results in T. G. Blackburn, A. J. MacLeod, A. Ilderton, B. King, S. Tang and M. Marklund, "Self-absorption of synchrotron radiation in a laser-irradiated plasma", arXiv:2005.00302 [physics.plasm-ph].
DOI: 10.5281/zenodo.3993061
title: Self-absorption of synchrotron radiation in a laser-irradiated plasma

description: Data and code required to reproduce the simulation results in T. G. Blackburn, A. J. MacLeod, A. Ilderton, B. King, S. Tang and M. Marklund, "Self-absorption of synchrotron radiation in a laser-irradiated plasma", arXiv:2005.00302 [physics.plasm-ph].
DOI: 10.6084/m9.figshare.13606196.v2
title: BC shape models by EMBS

description: The dataset of figures in the paper "<i>Constructing shapes and mixing structures of black carbon particles with applications to optical calculations</i>"
DOI: 10.6084/m9.figshare.13606196
title: Constructing shapes and mixing structures of black carbon particles with applications to optical calculations

description: The dataset of figures in the paper "<i>Constructing shapes and mixing structures of black carbon particles with applications to optical calculations</i>"
DOI: 10.6084/m9.figshare.13606196.v4
title: Constructing shapes and mixing structures of black carbon particles with applications to optical calculations

description: The dataset of figures in the paper "<i>Constructing shapes and mixing structures of black carbon particles with applications to optical calculations</i>"
DOI: 10.6084/m9.figshare.13606196.v3
title: Dataset of the BC optcal

description: The dataset of figures in the paper "<i>Constructing shapes and mixing structures of black carbon particles with applications to optical calculations</i>"
DOI: 10.6084/m9.figshare.13606757
title: inv.wholeChr_curation.total.hg38.bb

description: HR inversions
DOI: 10.6084/m9.figshare.13606757.v1
title: inv.wholeChr_curation.total.hg38.bb

description: HR inversions
DOI: 10.17037/data.00001997
title: Evaluation of the InTray and Compact Dry culture systems for the diagnosis of urinary tract infections - ARGUS study dataset

description: Antimicrobial resistance surveillance data is lacking from many resource-limited settings mainly due to limited laboratory testing. Novel culture systems may address some of the limitations of conventional culture media and expand the availability of microbiology services. This data was collected for an evaluation of the performance of two novel culture media: InTray COLOREX Screen/ESBL and Compact Dry for the detection of uropathogens and of extended-spectrum beta-lactamase (ESBL) producing organisms from urine samples.
description: Basic demographic data was collected during interviews with study participants who provided written informed consent prior to enrollment into the study. The dataset focuses on the results of laboratory testing. Urine cultures were performed using a reference media and the performance of two novel culture media was evaluated and compared to the reference. Culture result data was captured using case report forms.
DOI: 10.6084/m9.figshare.12019035.v117
title: How blood group A might be a risk and blood group O be protected from coronavirus (COVID-19) infections (how the virus invades the human body via ABO(H) blood group carbohydrates).

description: When according to the numbers of Wikipedia (although they are disputed) in countries like Chile, Ecuador, Colombia, Simbabwe and Mexico 59 to 85 percent of the people have blood group O and these countries officially publish extremely low COVID-19 cases and death rates per 1 million inhabitants, this may not alone result from insufficient investigations but might suggest a lower susceptibility of blood group O to the disease. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease. In the case that <i>O</i>-glycosylation plays a key role in the pathogenesis of coronavirus infections, as was discussed already 14 years ago in a SARS-CoV virus infection and is currently again predicted for SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, <i>O</i>-GalNAcα1-Ser/Thr-R, Tn (“T nouvelle”) antigenic structures. Although the ACE2 (angiotensin-converting-enzyme 2) protein is defined as the primary SARS-CoV receptor, it is the history of the amino acid serine, suggesting the actual or additional binding via an intermediate hybrid <i>O</i>-glycan: the protease-mobilized, virus-encoded serine molecule gets access to the host's N-acetyl-D-galactosamine (GalNAc) metabolism and the resulting intermediate, hybrid A-like/Tn structure performs the adhesion of the virus to host cells primarily independent of the ABO blood group, while the phenotype-determining sugars become the final glycosidic target. Individuals with blood group A cannot respond with either acquired or innate antibodies to the synthesis of A-like hybrid structures due to clonal selection and phenotypic accommodation of plasma proteins but perform a further (blood group-A-specific) hybrid binding. A first statistical study suggests that people with blood group A have a significantly higher risk for acquiring COVID-19, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups (Zhao, J. <i>et al., </i>2020). While these findings await confirmations, blood group O individuals, lacking the blood group-A-determining enzyme, may develop the least molecular contact with the virus and maintain the anti-A/Tn cross-reactive, complement-dependent isoagglutinin activity, which is exerted by the polyreactive, nonimmune immunoglobulin M (IgM), representing the humoral spearhead of innate immunity and a first line of defense.<b>Reference</b>: Zhao, J. <i>et al.</i> Relationship between the ABO Blood Group and the COVID-19 Susceptibility. <i>medRxiv</i> (2020) doi:10.1101/2020.03.11.20031096.<br>
DOI: 10.6084/m9.figshare.12019035.v119
title: How blood group A might be a risk and blood group O be protected from coronavirus (COVID-19) infections (how the virus invades the human body via ABO(H) blood group carbohydrates).

description: When according to the numbers of Wikipedia (although they are disputed) in countries like Chile, Ecuador, Colombia, Simbabwe and Mexico 59 to 85 percent of the people have blood group O and these countries officially publish extremely low COVID-19 cases and death rates per 1 million inhabitants, this may not alone result from insufficient investigations but might suggest a lower susceptibility of blood group O to the disease. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease. In the case that <i>O</i>-glycosylation plays a key role in the pathogenesis of coronavirus infections, as was discussed already 14 years ago in a SARS-CoV virus infection and is currently again predicted for SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, <i>O</i>-GalNAcα1-Ser/Thr-R, Tn (“T nouvelle”) antigenic structures. Although the ACE2 (angiotensin-converting-enzyme 2) protein is defined as the primary SARS-CoV receptor, it is the history of the amino acid serine, suggesting the actual or additional binding via an intermediate hybrid <i>O</i>-glycan: the TMPRSS2 (trans-membrane protease 2) host protease-mobilized, virus-encoded serine molecule gets access to the host's N-acetyl-D-galactosamine (GalNAc) metabolism and the resulting intermediate, hybrid A-like/Tn structure performs the adhesion of the virus to host cells primarily independent of the ABO blood group, while the phenotype-determining sugars become the final glycosidic target. Individuals with blood group A cannot respond with either acquired or innate antibodies to the synthesis of A-like hybrid structures due to clonal selection and phenotypic accommodation of plasma proteins but perform a further (blood group-A-specific) hybrid binding. A first statistical study suggests that people with blood group A have a significantly higher risk for acquiring COVID-19, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups (Zhao, J. <i>et al., </i>2020). While these findings await confirmations, blood group O individuals, lacking the blood group-A-determining enzyme, may develop the least molecular contact with the virus and maintain the anti-A/Tn cross-reactive, complement-dependent isoagglutinin activity, which is exerted by the polyreactive, nonimmune immunoglobulin M (IgM), representing the humoral spearhead of innate immunity and a first line of defense.<b>Reference</b>: Zhao, J. <i>et al.</i> Relationship between the ABO Blood Group and the COVID-19 Susceptibility. <i>medRxiv</i> (2020) doi:10.1101/2020.03.11.20031096.<br>
DOI: 10.6084/m9.figshare.12019035.v120
title: How blood group A might be a risk and blood group O be protected from coronavirus (COVID-19) infections (how the virus invades the human body via ABO(H) blood group carbohydrates).

description: When according to the numbers of Wikipedia (although they are disputed) in countries like Chile, Ecuador, Colombia, Simbabwe and Mexico 59 to 85 percent of the people have blood group O and these countries officially publish extremely low COVID-19 cases and death rates per 1 million inhabitants, this may not alone result from insufficient investigations but might suggest a lower susceptibility of blood group O to the disease. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease. In the case that <i>O</i>-glycosylation plays a key role in the pathogenesis of coronavirus infections, as was discussed already 14 years ago in a SARS-CoV virus infection and is currently again predicted for SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, <i>O</i>-GalNAcα1-Ser/Thr-R, Tn (“T nouvelle”) antigenic structures. Although the ACE2 (angiotensin-converting-enzyme 2) protein is defined as the primary SARS-CoV receptor, it is the history of the amino acid serine, suggesting the actual or additional binding via an intermediate hybrid <i>O</i>-glycan: the TMPRSS2 (transmembrane protease serine subtype 2) host protease-mobilized, virus-encoded serine molecule gets access to the host's N-acetyl-D-galactosamine (GalNAc) metabolism and the resulting intermediate, hybrid A-like/Tn structure performs the adhesion of the virus to host cells primarily independent of the ABO blood group, while the phenotype-determining sugars become the final glycosidic target. Individuals with blood group A cannot respond with either acquired or innate antibodies to the synthesis of A-like hybrid structures due to clonal selection and phenotypic accommodation of plasma proteins but perform a further (blood group-A-specific) hybrid binding. A first statistical study suggests that people with blood group A have a significantly higher risk for acquiring COVID-19, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups (Zhao, J. <i>et al., </i>2020). While these findings await confirmations, blood group O individuals, lacking the blood group-A-determining enzyme, may develop the least molecular contact with the virus and maintain the anti-A/Tn cross-reactive, complement-dependent isoagglutinin activity, which is exerted by the polyreactive, nonimmune immunoglobulin M (IgM), representing the humoral spearhead of innate immunity and a first line of defense.<b>Reference</b>: Zhao, J. <i>et al.</i> Relationship between the ABO Blood Group and the COVID-19 Susceptibility. <i>medRxiv</i> (2020) doi:10.1101/2020.03.11.20031096.<br>
DOI: 10.6084/m9.figshare.12019035.v121
title: How blood group A might be a risk and blood group O be protected from coronavirus (COVID-19) infections (how the virus invades the human body via ABO(H) blood group carbohydrates).

description: When according to the numbers of Wikipedia (although they are disputed) in countries like Chile, Ecuador, Colombia, Simbabwe and Mexico 59 to 85 percent of the people have blood group O and these countries officially publish extremely low COVID-19 cases and death rates per 1 million inhabitants, this may not alone result from insufficient investigations but might suggest a lower susceptibility of blood group O to the disease. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease. In the case that <i>O</i>-glycosylation plays a key role in the pathogenesis of coronavirus infections, as was discussed already 14 years ago in a SARS-CoV virus infection and is currently again predicted for SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, <i>O</i>-GalNAcα1-Ser/Thr-R, Tn (“T nouvelle”) antigenic structures. Although the ACE2 (angiotensin-converting-enzyme 2) protein is defined as the primary SARS-CoV receptor, it is the history of the amino acid serine, suggesting the actual or additional binding via an intermediate hybrid <i>O</i>-glycan: the TMPRSS2 (transmembrane protease serine subtype 2) host protease-mobilized, virus-encoded serine molecule gets access to the host's N-acetyl-D-galactosamine (GalNAc) metabolism and the resulting intermediate, hybrid A-like/Tn structure performs the adhesion of the virus to host cells primarily independent of the ABO blood group, while the phenotype-determining sugars become the final glycosidic target. Individuals with blood group A cannot respond with either acquired or innate antibodies to the synthesis of A-like hybrid structures due to clonal selection and phenotypic accommodation of plasma proteins but perform a further (blood group-A-specific) hybrid binding. A first statistical study suggests that people with blood group A have a significantly higher risk for acquiring COVID-19, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups (Zhao, J. <i>et al., </i>2020). While these findings await confirmations, blood group O individuals, lacking the blood group-A-determining enzyme, may develop the least molecular contact with the virus and maintain the anti-A/Tn cross-reactive, complement-dependent isoagglutinin activity, which is exerted by the polyreactive, nonimmune immunoglobulin M (IgM), representing the humoral spearhead of innate immunity and a first line of defense.<b>Reference</b>: Zhao, J. <i>et al.</i> Relationship between the ABO Blood Group and the COVID-19 Susceptibility. <i>medRxiv</i> (2020) doi:10.1101/2020.03.11.20031096.<br>
DOI: 10.6084/m9.figshare.12019035.v125
title: How blood group A might be a risk and blood group O be protected from coronavirus (COVID-19) infections (how the virus invades the human body via ABO(H) blood group carbohydrates).

description: Infection does not mean disease because for uncountable reasons the invasion of a pathogen does not always lead to disease symptoms. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease. In the case that <i>O</i>-glycosylation plays a key role in the pathogenesis of coronavirus infections, as was discussed already 14 years ago in a SARS-CoV virus infection and is currently again predicted for SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, <i>O</i>-GalNAcα1-Ser/Thr-R, Tn (“T nouvelle”) antigenic structures. Although the ACE2 (angiotensin-converting-enzyme 2) protein is defined as the primary SARS-CoV receptor, it is the history of the amino acid serine, suggesting the actual or additional binding via an intermediate hybrid <i>O</i>-glycan: the TMPRSS2 (transmembrane protease serine subtype 2) host protease-mobilized, virus-encoded serine molecule gets access to the host's N-acetyl-D-galactosamine (GalNAc) metabolism and the resulting intermediate, hybrid A-like/Tn structure performs the adhesion of the virus to host cells primarily independent of the ABO blood group, while the phenotype-determining sugars become the final glycosidic target. Individuals with blood group A cannot respond with either acquired or innate antibodies to the synthesis of A-like hybrid structures due to clonal selection and phenotypic accommodation of plasma proteins but perform a further (blood group-A-specific) hybrid binding. A first statistical study suggests that people with blood group A have a significantly higher risk for acquiring COVID-19, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups (Zhao, J. <i>et al., 2020). </i>SARS-Cov-2 (COVID-19) infections may be considered an evolutionary selective disease, contributing to the present-day world distribution of the human ABO(H) blood groups, which has arisen through blood group-related life-threatening diseases<sup> </sup>over millions of years. While the synthesis of the blood group AB enables the strongest contact with a pathogen and molecularly precluding any isoagglutinin activity, makes this group the least protected and the smallest among the ABO blood groups, blood group O(H) individuals develop the least contact with the pathogen; maintaining the isoagglutinins, they rarer develop severe disease and survive this coevolution in an immunological balance with a pathogen as the largest blood group worldwide.<i><br></i><b>Reference</b>: Zhao, J. <i>et al.</i> Relationship between the ABO Blood Group and the COVID-19 Susceptibility. <i>medRxiv</i> (2020) doi:10.1101/2020.03.11.20031096.<br>